National Institutes of Health

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in developing noninvasive electrophysiology devices that monitor, control, and repair peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions more effectively, track the progression of symptoms over time, and select tailored treatments for individual patients. This innovative approach enhances the ability of healthcare providers to address nerve-related health issues with greater precision and efficiency.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in developing noninvasive electrophysiology devices that monitor, control, and repair peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions more effectively, track the progression of symptoms over time, and select tailored treatments for individual patients. This innovative approach enhances the ability of healthcare providers to address nerve-related health issues with greater precision and efficiency.

Founded in 1975, Morehouse School of Medicine is a private medical school located in Atlanta, Georgia. It offers a Doctor of Medicine (MD) program with specializations in Family Medicine, Internal Medicine, Obstetrics and Gynecology, Pediatrics, Psychiatry and Behavioral Sciences, and Surgery. The school also provides master's degrees in Public Health and Biomedical Sciences. Morehouse is committed to educating minority students and reducing health disparities.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in developing noninvasive electrophysiology devices that monitor, control, and repair peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions more effectively, track the progression of symptoms over time, and select tailored treatments for individual patients. This innovative approach enhances the ability of healthcare providers to address nerve-related health issues with greater precision and efficiency.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

Augusta University, established in 1785 as the Academy of Richmond County, is a public institution located in Augusta, Georgia. It offers a wide range of educational programs, including associate’s, bachelor’s, master’s, and doctoral degrees across various disciplines. The university is renowned for its health sciences programs, particularly through its Medical College of Georgia, which is one of the oldest medical colleges in the United States. Augusta University also provides extensive continuing education opportunities, with a focus on healthcare careers, as well as personal enrichment courses. The institution is committed to groundbreaking research and patient-centered clinical expertise, operating from three campuses in Augusta and satellite locations across the state. It is home to Georgia's only public academic medical center, attracting nearly 9,000 students annually.

Metaclipse Therapeutics develops next-generation cancer immunotherapies that use patient-derived tumor-membrane vesicles to activate the immune system against metastatic cancer. The autologous platform creates nanovesicles prepared from a patient's tumor tissue and augments them with proprietary immunostimulatory proteins to deliver tumor antigens and immune signals simultaneously. The approach is designed to generate robust, tumor-specific immunity that can destroy or suppress metastatic cancer cells originating from the patient's primary tumor. The company describes Membrex as a novel, personalized immunotherapy tailored to individual tumors, with aim of synergy with checkpoint inhibitors. Metaclipse operates in the preclinical/early development stage and seeks licensing partnerships with major pharmaceutical companies after establishing safety and efficacy. The technology targets multiple cancer types, including breast, prostate, renal cancer, melanoma, lymphoma, and ovarian cancer. Metaclipse is based in Atlanta, Georgia, focusing on therapies that activate the body's immune response to metastatic disease.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Norcross, Georgia, dedicated to developing innovative therapies for fibrotic diseases, cancer, and related conditions. The company's leading product candidate, GR-MD-02, is a galectin-3 inhibitor currently undergoing Phase III clinical trials for treating liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for cancer therapeutics. In addition to GR-MD-02, Galectin Therapeutics is developing GM-CT-01, which is in the preclinical stage and aims to address cardiac and vascular fibrosis, along with exploring treatments for psoriasis. The company leverages its expertise in galectin science and unique carbohydrate technology to create drug candidates that specifically target galectin proteins, which play significant roles in various diseases. By focusing on conditions with serious consequences and limited treatment options, Galectin Therapeutics aims to establish efficient clinical development pathways and seeks partnerships to advance its programs.